On Friday, the US Food and Drug Administration announced drugs Wegovy and Ozempic by Novo Nordisk are no longer in shortage.

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

Weight loss drugs linked to dozens of deaths - The medical director of the NHS has warned of the side effects of weight loss ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

With the rise of obesity drugs a pair of Penn State researchers set out to answer a question: could drugs aimed at weight ...

Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...

There’s evidence that the demographic of people on the drugs overlaps with those who like to spend, a group some analysts ...

Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...

We recently published a list of Top 10 Stocks to Buy According to Sustainable Insight Capital Management. In this article, we ...

Eli Lilly's stock offers high growth potential, driven by GLP-1 therapies and strong R&D efforts. Read why LLY stock is ...

Sustainable Insight Capital Management (SICM) focuses on institutional investments, offering both long-only and long-short strategies in public equities.